Community of Practice for Neuromuscular Allied Healthcare Members: MDC and NMD4C Begin Consultations
The Neuromuscular Disease Network for Canada in partnership with Muscular Dystrophy Canada, is investigating ways to better support allied healthcare professionals that work with clients/patients affected by neuromuscular disorders and their families.
We wish to introduce and implement a Community of Practice for allied healthcare professionals this year, but first we would like to complete a needs assessment and seek your valued input. Please take this brief survey before April 15th:
English: https://www.surveymonkey.com/r/NMAlliedHealthConsultation
French: https://www.surveymonkey.com/r/DMCCommunautedePratique
We will also be hosting virtual engagement sessions on April 6th and 7th to provide allied healthcare professionals with an opportunity to share their professional experiences, questions, concerns, and comments. If you would like to learn more about these consultations, please email Homira Osman at
We also ask that you circulate the above survey with your colleagues with clients/patients affected by neuromuscular disorders.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.